# US 2008/0306146 A1 · Dosing Regimens for Cox-2 Inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306146 A1
- Document ID: US20080306146A1
- Status: Published application
- Kind: A1
- Application number: 12/092,304
- Filed: 2006-10-31
- Published: 2008-12-11
- Earliest claimed: 2005-11-02
- Assignees: Amorepacific Corporation
- Inventors: Kyung-Min Lim; Mi-Young Park; Kl-Wha Lee; Sung-ll Kim; Shin Chung
- Web page: https://patentgrep.com/patent/US20080306146A1

## CPC

- C07D 307/58: One oxygen atom, e.g. butenolide
- A61K 31/341: not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a potent cyclooxygenase-2 inhibitor and dosing regimens thereof to safely treat cyclooxygenase-2 mediated disorders.

## Claims

### Claim 1

A method to treat a COX-2 mediated disorder by administering to a subject Compound A, or a pharmaceutically acceptable salt or composition thereof according to a dosing regimen adopting a combination of loading dose and daily maintenance dose so as to maintain an essentially constant therapeutic plasma level of Compound A:

### Claim 2 (depends on 1)

Within claim 1, a method to treat a COX-2 mediated disorder by administering to a subject Compound A, or a pharmaceutically acceptable salt or composition thereof according to a dosing regimen adopting a combination of loading dose and daily maintenance dose so as to maintain an essentially constant therapeutic plasma level of Compound A, wherein the loading dose is up to 15 mg and the daily maintenance dose is not more than 20% of the loading dose per day.

### Claim 3 (depends on 1)

Within claim 1, a method to treat a COX-2 mediated disorder requiring a long term treatment by administering to a subject Compound A, or a pharmaceutically acceptable salt or composition thereof according to a dosing regimen adopting a combination of loading dose and daily maintenance dose so as to maintain an essentially constant therapeutic plasma level of Compound A.

### Claim 4 (depends on 2)

Within claim 2, a method to treat a COX-2 mediated disorder requiring a long term treatment by administering to a subject Compound A, or a pharmaceutically acceptable salt or composition thereof according to a dosing regimen adopting a combination of loading dose and daily maintenance dose so as to maintain an essentially constant therapeutic plasma level of Compound A, wherein the loading dose is up to 15 mg and the daily maintenance dose is not more than 20% of the loading dose per day.
The present invention relates to a potent cyclooxygenase-2 inhibitor and dosing regimens thereof to safely treat cyclooxygenase-2 mediated disorders.
